| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, CCR | 8 | 2021 | 24 | 2.380 |
Why?
|
| Chemokines, CC | 10 | 2019 | 53 | 2.360 |
Why?
|
| Prostatic Neoplasms | 11 | 2019 | 1068 | 1.830 |
Why?
|
| Receptors, Chemokine | 8 | 2016 | 72 | 1.580 |
Why?
|
| Neoplasm Invasiveness | 11 | 2016 | 284 | 1.480 |
Why?
|
| Cell Movement | 16 | 2019 | 640 | 1.440 |
Why?
|
| Apoptosis | 9 | 2019 | 1541 | 1.340 |
Why?
|
| Colonic Neoplasms | 3 | 2025 | 223 | 1.100 |
Why?
|
| Chemokines | 5 | 2017 | 97 | 0.970 |
Why?
|
| Cell Line, Tumor | 18 | 2025 | 2598 | 0.960 |
Why?
|
| Receptors, Virus | 2 | 2016 | 22 | 0.950 |
Why?
|
| Chemokines, CXC | 6 | 2016 | 36 | 0.950 |
Why?
|
| Ovarian Neoplasms | 4 | 2024 | 406 | 0.920 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 933 | 0.910 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2015 | 130 | 0.890 |
Why?
|
| Immunotherapy | 2 | 2024 | 137 | 0.880 |
Why?
|
| Antineoplastic Agents | 4 | 2019 | 979 | 0.790 |
Why?
|
| Metalloproteases | 3 | 2015 | 17 | 0.770 |
Why?
|
| Neutrophils | 3 | 2022 | 141 | 0.740 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 479 | 0.690 |
Why?
|
| Neoplasm Metastasis | 4 | 2019 | 233 | 0.670 |
Why?
|
| Breast Neoplasms | 5 | 2019 | 1679 | 0.620 |
Why?
|
| Receptors, Scavenger | 2 | 2016 | 15 | 0.610 |
Why?
|
| Receptors, CXCR5 | 4 | 2014 | 15 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 209 | 0.590 |
Why?
|
| Proanthocyanidins | 1 | 2018 | 3 | 0.590 |
Why?
|
| Cytokines | 8 | 2017 | 661 | 0.560 |
Why?
|
| Receptors, CXCR3 | 6 | 2016 | 31 | 0.560 |
Why?
|
| Quercetin | 1 | 2018 | 46 | 0.560 |
Why?
|
| Chemokine CXCL13 | 5 | 2014 | 18 | 0.540 |
Why?
|
| Receptors, CXCR4 | 3 | 2013 | 74 | 0.530 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2018 | 160 | 0.530 |
Why?
|
| Humans | 38 | 2025 | 42163 | 0.520 |
Why?
|
| Receptors, CCR6 | 1 | 2016 | 3 | 0.500 |
Why?
|
| Prostate | 4 | 2016 | 152 | 0.500 |
Why?
|
| Andrographis | 1 | 2016 | 4 | 0.490 |
Why?
|
| Receptors, CXCR | 1 | 2016 | 6 | 0.490 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2016 | 17 | 0.490 |
Why?
|
| Cytoskeleton | 1 | 2016 | 111 | 0.470 |
Why?
|
| Epithelial Cells | 3 | 2016 | 426 | 0.470 |
Why?
|
| Cell Adhesion | 3 | 2016 | 237 | 0.470 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 290 | 0.460 |
Why?
|
| Diterpenes | 1 | 2016 | 94 | 0.460 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 114 | 0.450 |
Why?
|
| Matrix Metalloproteinases | 5 | 2019 | 49 | 0.430 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 134 | 0.430 |
Why?
|
| Facial Neoplasms | 1 | 2013 | 5 | 0.410 |
Why?
|
| Disease Progression | 5 | 2019 | 661 | 0.410 |
Why?
|
| Cheek | 1 | 2013 | 13 | 0.410 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 22 | 0.410 |
Why?
|
| Cell Survival | 4 | 2018 | 934 | 0.390 |
Why?
|
| Prostatic Hyperplasia | 2 | 2009 | 32 | 0.390 |
Why?
|
| Interleukin-10 | 5 | 2025 | 86 | 0.380 |
Why?
|
| Signal Transduction | 7 | 2025 | 2111 | 0.380 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 84 | 0.380 |
Why?
|
| Fluorouracil | 2 | 2025 | 46 | 0.370 |
Why?
|
| RNA, Messenger | 8 | 2019 | 1265 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 297 | 0.370 |
Why?
|
| Caspase 3 | 2 | 2010 | 226 | 0.360 |
Why?
|
| Chemokine CCL20 | 2 | 2025 | 9 | 0.360 |
Why?
|
| Tumor Cells, Cultured | 6 | 2016 | 506 | 0.350 |
Why?
|
| Etoposide | 1 | 2010 | 21 | 0.340 |
Why?
|
| Cisplatin | 1 | 2011 | 91 | 0.340 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 100 | 0.330 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 6 | 2014 | 45 | 0.320 |
Why?
|
| Cell Proliferation | 8 | 2019 | 1420 | 0.320 |
Why?
|
| Male | 17 | 2021 | 22779 | 0.310 |
Why?
|
| Integrins | 1 | 2009 | 54 | 0.300 |
Why?
|
| Caspase 9 | 1 | 2009 | 30 | 0.300 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2009 | 52 | 0.290 |
Why?
|
| Drug Synergism | 2 | 2019 | 189 | 0.280 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 287 | 0.280 |
Why?
|
| Streptococcus pneumoniae | 4 | 2014 | 34 | 0.280 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2019 | 35 | 0.270 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 649 | 0.260 |
Why?
|
| Flow Cytometry | 4 | 2016 | 411 | 0.250 |
Why?
|
| Immunity, Mucosal | 6 | 2008 | 52 | 0.250 |
Why?
|
| Colitis | 4 | 2008 | 69 | 0.240 |
Why?
|
| Pneumococcal Infections | 4 | 2014 | 33 | 0.240 |
Why?
|
| Neoplasms | 2 | 2021 | 1341 | 0.240 |
Why?
|
| Chemokine CCL5 | 4 | 2011 | 40 | 0.240 |
Why?
|
| Bacterial Proteins | 4 | 2014 | 580 | 0.240 |
Why?
|
| Plant Extracts | 2 | 2021 | 303 | 0.240 |
Why?
|
| Female | 25 | 2024 | 24018 | 0.240 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 26 | 0.230 |
Why?
|
| Prognosis | 3 | 2018 | 850 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 1112 | 0.220 |
Why?
|
| Immunoenzyme Techniques | 3 | 2016 | 111 | 0.220 |
Why?
|
| Membrane Proteins | 3 | 2019 | 548 | 0.220 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 366 | 0.210 |
Why?
|
| Immunologic Factors | 2 | 2022 | 50 | 0.200 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 683 | 0.200 |
Why?
|
| Chemokine CXCL10 | 3 | 2015 | 38 | 0.200 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2014 | 59 | 0.200 |
Why?
|
| Antigens, CD34 | 2 | 2015 | 19 | 0.200 |
Why?
|
| Nanotechnology | 1 | 2024 | 176 | 0.200 |
Why?
|
| Mice | 18 | 2014 | 6490 | 0.190 |
Why?
|
| Sorghum | 1 | 2022 | 3 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2010 | 456 | 0.190 |
Why?
|
| Saccharum | 1 | 2022 | 7 | 0.190 |
Why?
|
| Interferon-gamma | 7 | 2014 | 268 | 0.180 |
Why?
|
| Momordica charantia | 1 | 2021 | 17 | 0.180 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 2011 | 20 | 0.170 |
Why?
|
| Yoga | 1 | 2021 | 33 | 0.170 |
Why?
|
| Complementary Therapies | 1 | 2021 | 51 | 0.160 |
Why?
|
| Blotting, Western | 4 | 2016 | 884 | 0.150 |
Why?
|
| Ovary | 1 | 2019 | 112 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2010 | 276 | 0.140 |
Why?
|
| Chemokine CXCL11 | 2 | 2016 | 7 | 0.140 |
Why?
|
| Mycobacterium avium subsp. paratuberculosis | 2 | 2008 | 6 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 301 | 0.130 |
Why?
|
| Killer Cells, Natural | 2 | 2008 | 99 | 0.130 |
Why?
|
| Epitope Mapping | 2 | 2014 | 31 | 0.130 |
Why?
|
| Animals | 18 | 2014 | 16695 | 0.130 |
Why?
|
| Models, Biological | 2 | 2017 | 711 | 0.130 |
Why?
|
| Membrane Transport Proteins | 2 | 2009 | 98 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 8 | 2014 | 686 | 0.130 |
Why?
|
| NF-kappa B | 1 | 2019 | 355 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 928 | 0.120 |
Why?
|
| Cyclin B1 | 1 | 2016 | 18 | 0.120 |
Why?
|
| CDC2 Protein Kinase | 1 | 2016 | 20 | 0.120 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 25 | 0.120 |
Why?
|
| Cyclins | 1 | 2016 | 37 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 32 | 0.120 |
Why?
|
| Retinoblastoma Protein | 1 | 2016 | 29 | 0.120 |
Why?
|
| Cell Growth Processes | 1 | 2015 | 43 | 0.120 |
Why?
|
| ADAM Proteins | 1 | 2015 | 20 | 0.120 |
Why?
|
| Heme | 1 | 2015 | 72 | 0.120 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 64 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 139 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1266 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 170 | 0.110 |
Why?
|
| Malaria, Falciparum | 1 | 2015 | 91 | 0.110 |
Why?
|
| Antioxidants | 1 | 2018 | 439 | 0.110 |
Why?
|
| Stem Cells | 1 | 2015 | 151 | 0.110 |
Why?
|
| Histones | 1 | 2016 | 194 | 0.110 |
Why?
|
| Th1 Cells | 4 | 2008 | 97 | 0.110 |
Why?
|
| Tissue Array Analysis | 2 | 2011 | 79 | 0.110 |
Why?
|
| Immunodominant Epitopes | 1 | 2014 | 28 | 0.110 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1586 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 330 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 239 | 0.100 |
Why?
|
| Antibodies, Bacterial | 3 | 2008 | 117 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2013 | 46 | 0.100 |
Why?
|
| Hematuria | 1 | 2013 | 6 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 81 | 0.100 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 58 | 0.100 |
Why?
|
| Protein Subunits | 1 | 2013 | 93 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2016 | 973 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2010 | 462 | 0.100 |
Why?
|
| Protein Binding | 4 | 2021 | 1076 | 0.090 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 18 | 0.090 |
Why?
|
| Models, Immunological | 1 | 2011 | 21 | 0.090 |
Why?
|
| Mice, Knockout | 7 | 2011 | 1010 | 0.090 |
Why?
|
| Epitopes | 1 | 2011 | 155 | 0.090 |
Why?
|
| Dendritic Cells | 3 | 2008 | 130 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2011 | 206 | 0.080 |
Why?
|
| Interleukin-6 | 2 | 2009 | 165 | 0.080 |
Why?
|
| Chlamydia muridarum | 2 | 2008 | 104 | 0.080 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2010 | 33 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2010 | 50 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 167 | 0.080 |
Why?
|
| Peptides | 2 | 2010 | 357 | 0.080 |
Why?
|
| Mice, Nude | 1 | 2010 | 403 | 0.080 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2009 | 13 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2009 | 54 | 0.080 |
Why?
|
| Mice, SCID | 1 | 2009 | 158 | 0.070 |
Why?
|
| Technology, Pharmaceutical | 1 | 2008 | 32 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2009 | 115 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2009 | 127 | 0.070 |
Why?
|
| Nasal Mucosa | 2 | 2004 | 31 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 1 | 2009 | 145 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2008 | 378 | 0.070 |
Why?
|
| Paratuberculosis | 1 | 2007 | 4 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 140 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 339 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 2 | 2004 | 117 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 26 | 0.060 |
Why?
|
| Lymphocyte Activation | 4 | 2014 | 244 | 0.060 |
Why?
|
| Chlamydia Infections | 1 | 2008 | 199 | 0.060 |
Why?
|
| Plasmodium yoelii | 1 | 2005 | 10 | 0.060 |
Why?
|
| Carrier State | 1 | 2006 | 33 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 273 | 0.060 |
Why?
|
| Cerebellum | 1 | 2005 | 78 | 0.060 |
Why?
|
| Proteins | 1 | 2008 | 383 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2005 | 31 | 0.060 |
Why?
|
| Malaria | 1 | 2005 | 90 | 0.060 |
Why?
|
| Chemokine CXCL12 | 1 | 2004 | 32 | 0.060 |
Why?
|
| Immunoglobulin G | 4 | 2008 | 253 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2005 | 68 | 0.060 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2004 | 21 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 5 | 2011 | 1804 | 0.050 |
Why?
|
| Enterocolitis | 1 | 2003 | 2 | 0.050 |
Why?
|
| Adoptive Transfer | 1 | 2003 | 50 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2004 | 135 | 0.050 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2002 | 16 | 0.050 |
Why?
|
| Carbohydrates | 1 | 2022 | 32 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2014 | 31 | 0.050 |
Why?
|
| Biomass | 1 | 2022 | 66 | 0.050 |
Why?
|
| Oleanolic Acid | 1 | 2021 | 3 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 599 | 0.050 |
Why?
|
| Surface Plasmon Resonance | 1 | 2021 | 35 | 0.040 |
Why?
|
| Immunoglobulin A | 3 | 2008 | 63 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2008 | 379 | 0.040 |
Why?
|
| Antibody Formation | 3 | 2008 | 75 | 0.040 |
Why?
|
| Immunity, Cellular | 3 | 2008 | 73 | 0.040 |
Why?
|
| Spleen | 2 | 2014 | 199 | 0.040 |
Why?
|
| Antigens, Bacterial | 3 | 2007 | 144 | 0.040 |
Why?
|
| Aged | 1 | 2013 | 7982 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2021 | 64 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 421 | 0.040 |
Why?
|
| Medically Underserved Area | 1 | 2021 | 118 | 0.040 |
Why?
|
| Binding Sites | 1 | 2021 | 670 | 0.040 |
Why?
|
| Ovalbumin | 3 | 2004 | 47 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 1188 | 0.040 |
Why?
|
| Phenotype | 1 | 2022 | 774 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 1559 | 0.040 |
Why?
|
| Up-Regulation | 3 | 2005 | 534 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2008 | 1554 | 0.030 |
Why?
|
| Serum Amyloid A Protein | 2 | 2008 | 14 | 0.030 |
Why?
|
| Receptors, CCR5 | 2 | 2006 | 64 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2007 | 91 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2007 | 66 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2008 | 181 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2004 | 76 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2014 | 27 | 0.030 |
Why?
|
| Ligands | 2 | 2007 | 387 | 0.030 |
Why?
|
| Interleukins | 1 | 2014 | 37 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 105 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2014 | 73 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2014 | 185 | 0.030 |
Why?
|
| Receptor, PAR-1 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cell Division | 2 | 2005 | 314 | 0.030 |
Why?
|
| Thrombin | 1 | 2013 | 28 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 33 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2004 | 122 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2013 | 47 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2013 | 139 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 1066 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 1416 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 1516 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2006 | 1617 | 0.020 |
Why?
|
| Chemokine CXCL5 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 875 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2010 | 12 | 0.020 |
Why?
|
| GTPase-Activating Proteins | 1 | 2010 | 29 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2010 | 107 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 116 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1058 | 0.020 |
Why?
|
| Absorption | 1 | 2008 | 22 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Drug Stability | 1 | 2008 | 127 | 0.020 |
Why?
|
| Cell Separation | 1 | 2008 | 94 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 256 | 0.020 |
Why?
|
| Liposomes | 1 | 2008 | 130 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 23 | 0.020 |
Why?
|
| Child | 1 | 2015 | 3381 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 68 | 0.020 |
Why?
|
| Particle Size | 1 | 2008 | 267 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2008 | 106 | 0.020 |
Why?
|
| Polymers | 1 | 2008 | 151 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2008 | 101 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2008 | 169 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 138 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2006 | 69 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 131 | 0.020 |
Why?
|
| Receptors, CCR1 | 1 | 2005 | 8 | 0.020 |
Why?
|
| Receptors, CCR3 | 1 | 2005 | 10 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 106 | 0.020 |
Why?
|
| Middle Aged | 1 | 2021 | 11819 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 295 | 0.010 |
Why?
|
| Adhesins, Bacterial | 1 | 2005 | 20 | 0.010 |
Why?
|
| Chemokine CCL1 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Chemokine CXCL6 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2004 | 16 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 310 | 0.010 |
Why?
|
| Chlamydia trachomatis | 1 | 2005 | 69 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2004 | 50 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 5950 | 0.010 |
Why?
|
| Leukocytes | 1 | 2004 | 79 | 0.010 |
Why?
|
| Reaction Time | 1 | 2004 | 151 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 279 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 2003 | 19 | 0.010 |
Why?
|
| Immune Sera | 1 | 2003 | 56 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2004 | 168 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 58 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 183 | 0.010 |
Why?
|
| Apolipoproteins | 1 | 2003 | 22 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 221 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2003 | 168 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 292 | 0.010 |
Why?
|
| Crohn Disease | 1 | 2003 | 69 | 0.010 |
Why?
|
| Chemokine CCL3 | 1 | 2002 | 14 | 0.010 |
Why?
|
| Chemokine CCL4 | 1 | 2002 | 19 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2002 | 17 | 0.010 |
Why?
|
| Feces | 1 | 2003 | 126 | 0.010 |
Why?
|
| Nanoparticles | 1 | 2008 | 449 | 0.010 |
Why?
|
| Proteomics | 1 | 2005 | 363 | 0.010 |
Why?
|
| Weight Loss | 1 | 2003 | 138 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2002 | 89 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 658 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1848 | 0.010 |
Why?
|
| Adult | 1 | 2008 | 13458 | 0.010 |
Why?
|